SMOB recommendations for prioritization of 2.4 mg Semaglutide therapy
Bernd Schultes1, Marco Bueter2,3, Lucie Favre4,5,6, Katharina Timper7,8 for the collaborative task force “prioritization of anti-obesity pharmacotherapy” of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB) Background The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product Wegovy® (2.4 mg semaglutide) demands a prioritization by means of which […]
Plus